Gene therapy for inherited hyperbilirubinemias

Namita Roy-Chowdhury, Ajit Kadakol, Baljit S. Sappal, Narsing R. Thummala, Siddhartha S. Ghosh, Sung W. Lee, Jayanta Roy-Chowdhury

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Crigler-Najjar syndrome type 1 (CN-1) is a potentially lethal condition, and is the only inherited disorder of bilirubin metabolism that needs treatment beyond the neonatal period. Currently, orthotopic liver transplantation is the only available cure for CN-1. Because the liver architecture is not disturbed in CN-1 and partial correction of bilirubin-UDP-glucuronosyltransferase (UGT1A1) activity is expected to be sufficient for protection against kernicterus, cell and gene therapies are being developed using the Gunn rat as an animal model of the disease. Ex vivo gene therapy based on the transplantation of genetically manipulated hepatocytes and in vivo gene transfer using recombinant adenovirus and Simian virus 40 (SV40)–based vectors have yielded significant success. The novel strategy of in vivo site-directed mutagenesis has also resulted in modest, but significant, correction of the genetic abnormality. Newer viral and nonviral gene delivery methods are being explored and have been discussed in brief. In summary, effective gene therapy methods have been validated in Gunn rats. Despite considerable remaining hurdles, gene therapy for CN-1 could become a clinical reality by the turn of this decade.

Original languageEnglish (US)
Pages (from-to)S114-S118
JournalJournal of Perinatology
StatePublished - Dec 1 2001

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology


Dive into the research topics of 'Gene therapy for inherited hyperbilirubinemias'. Together they form a unique fingerprint.

Cite this